|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis: Type 2 Diabetes
Medpredict, Dec 2007, Pages: 119
The major theme for this report is the interplay between diabetes and cardiovascular disease; specifically coronary artery disease.
- Recent changes to the ADA guidelines highlight the diabetic’s increased risk for CAD. In light of these guidelines our Panel discusses the unmet needs and the endocrinologist’s emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH).
- Incretins will dominate new launches for HbA1c lowering drugs for the next few years. The Panel discusses the significance of targeting DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists. Strengths and weaknesses of new monotherapies and combination approaches are discussed.
- These new orals and parenterals will put pressure on established products, including metformin, sulfonylureas and TZDs. The Panel offers insight into how each fits into the diabetes / CAD paradigm.
- Exubera established the proof-of-concept for non-injectable insulin therapy. The Panel describes why it has failed commercially, and benchmarks next-generation insulins.
- The other new mechanism most of interest to the Panel was inhibition of SGLT. While still very early in development the Panel shared key insights about the future for this class.
- Finally, the Panel comments on the importance of Beta cell protection or regeneration.
Customers who bought this item also bought
Impact of Inhaled Insulin on the Insulin Market
Innovations in the Management of Diabetes: Next Generation Treatments and Market Dynamics
Competitor Analysis: Diabetes Drug Pipeline
The Diabetes Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Diabetes
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Diabetes Market Forecast to 2013
Thought Leader Insight & Analysis: Obesity
The Diabetes Market Outlook to 2011
Diabetes Drug Discoveries: what the future holds
Pipeline Insight: Non-Insulin Antidiabetics - Type 2 Diabetes Unlikely To Develop Into a Switch Market
|
|
|
|
